针对表观基因组,以重振T细胞,用于癌症免疫疗法
Dian Xiong1, Lu Zhang2, Zhi-Jun Sun3,4
1State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430079, China.
癌症免疫疗法面临来自T细胞枯竭的挑战,这是由瘤微环境驱动的功能障碍. 本综述探讨了T细胞枯竭背后的表观遗传机制,并讨论了针对表观遗传调节者的改善癌症免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 用免疫检查点抑制剂 (ICI) 进行的癌症免疫疗法改变了癌症治疗.
- 治疗疗效受到T细胞枯竭的限制,这是CD8+瘤透淋巴细胞 (TILs) 的功能障碍.
- 瘤发生和瘤免疫微环境 (TIME) 通过表观遗传变化导致T细胞耗尽.
研究的目的:
- 审查瘤微环境中驱动T细胞枯竭的表观遗传机制.
- 讨论在癌症免疫治疗中准表观遗传调节者的治疗潜力.
- 概述了将表观遗传疗法与免疫刺激剂结合的进展.
主要方法:
- 在T细胞枯竭中的表观遗传机制的文献综述.
- 分析TIME因素与表观遗传修饰之间的相互作用.
- 综合当前和未来的治疗策略.
主要成果:
- 表观遗传重编程是T细胞疲劳的关键驱动因素,受各种时间因素的影响.
- 准表观遗传调节器是克服ICI耐药性的有希望的策略.
- 涉及表观遗传剂和免疫刺激药物的组合疗法显示出潜力.
结论:
- 表观遗传机制是理解和克服癌症T细胞枯竭的核心.
- 向表观遗传调节器提供了一种新的方法来提高癌症免疫疗法的疗效.
- 未来的研究应该专注于开发组合治疗模式,以改善患者的治疗结果.
更多相关视频
06:10Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment
Mitogens and the Cell Cycle
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
